[go: up one dir, main page]

MX2023003010A - Composiciones para compuestos de agente terapeutico de molecula peque?a. - Google Patents

Composiciones para compuestos de agente terapeutico de molecula peque?a.

Info

Publication number
MX2023003010A
MX2023003010A MX2023003010A MX2023003010A MX2023003010A MX 2023003010 A MX2023003010 A MX 2023003010A MX 2023003010 A MX2023003010 A MX 2023003010A MX 2023003010 A MX2023003010 A MX 2023003010A MX 2023003010 A MX2023003010 A MX 2023003010A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
small molecule
molecule therapeutic
organic acid
compositions
Prior art date
Application number
MX2023003010A
Other languages
English (en)
Inventor
Gregory A Watkins
Original Assignee
Delpor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delpor Inc filed Critical Delpor Inc
Publication of MX2023003010A publication Critical patent/MX2023003010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición que comprende una suspensión acuosa que comprende un agente terapéutico de molécula pequeña y un ácido orgánico. El agente terapéutico de molécula pequeña es una base y que tiene una solubilidad en agua a temperatura ambiente de menos de aproximadamente 1.0 g/L. El ácido orgánico tiene una solubilidad en agua a temperatura ambiente de entre 0.1 y 10, tiene una masa molar de menos de 500 gramos por mol, y/o mantiene un pH de la suspensión en su ambiente de uso de entre 3.0-6.5. El ácido orgánico mejora la solubilidad del agente terapéutico de molécula pequeña y cuando se presenta en exceso estequiométrico, el ácido orgánico conduce la liberación del agente terapéutico de molécula pequeña en un ambiente amortiguado de uso por periodos prolongados de, por ejemplo, seis meses hasta un año. También se describen dispositivos que comprenden las composiciones y métodos de tratamiento.
MX2023003010A 2016-09-23 2019-03-15 Composiciones para compuestos de agente terapeutico de molecula peque?a. MX2023003010A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662399083P 2016-09-23 2016-09-23

Publications (1)

Publication Number Publication Date
MX2023003010A true MX2023003010A (es) 2023-04-10

Family

ID=60083440

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003052A MX2019003052A (es) 2016-09-23 2017-09-22 Composiciones para compuestos de agente terapeutico de molecula pequeña.
MX2023003010A MX2023003010A (es) 2016-09-23 2019-03-15 Composiciones para compuestos de agente terapeutico de molecula peque?a.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019003052A MX2019003052A (es) 2016-09-23 2017-09-22 Composiciones para compuestos de agente terapeutico de molecula pequeña.

Country Status (10)

Country Link
US (2) US20190224322A1 (es)
EP (1) EP3515407A1 (es)
JP (3) JP7716175B2 (es)
KR (2) KR20190066608A (es)
CN (1) CN109890365A (es)
AU (1) AU2017331340B2 (es)
BR (1) BR112019005542A2 (es)
CA (1) CA3037531A1 (es)
MX (2) MX2019003052A (es)
WO (1) WO2018057968A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102868737B1 (ko) * 2018-02-27 2025-10-14 델포어, 인코포레이티드 소분자 치료제 화합물을 위한 조성물
CA3149545A1 (en) * 2019-08-28 2021-03-04 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
TWI820673B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑口溶膜組合物、其製備方法及用途
US20230052375A1 (en) * 2021-08-13 2023-02-16 Mott Corporation Drug delivery assembly for extended drug delivery and tunability
WO2025101908A1 (en) 2023-11-09 2025-05-15 Delpor, Inc. Method of treatment with risperidone via an implantable subcutaneous device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US7592300B2 (en) 2003-11-24 2009-09-22 The Dial Corporation Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
PL377084A1 (pl) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent Nowe związki olanzapiny i sposób ich wytwarzania
EP2195318A2 (en) * 2007-10-09 2010-06-16 Cipla Limited Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CA2750028C (en) * 2009-01-20 2019-05-07 Guochuan Emil Tsai Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
EP2405967B1 (en) 2009-03-12 2020-09-23 Delpor, Inc. Implantable device for long-term delivery of drugs
JP5664871B2 (ja) * 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
US8343516B2 (en) * 2009-06-26 2013-01-01 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
SMT202100679T1 (it) * 2010-05-31 2022-01-10 Laboratorios Farmaceuticos Rovi S A Composizioni per impianti biodegradabili in-situ iniettabili
KR101408370B1 (ko) * 2012-06-26 2014-06-18 주식회사지씨비 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
KR20150095622A (ko) * 2012-09-28 2015-08-21 델포어, 인코포레이티드 항정신병 제제의 지속 방출을 위한 장치 및 방법
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂

Also Published As

Publication number Publication date
BR112019005542A2 (pt) 2019-06-18
KR20230093349A (ko) 2023-06-27
EP3515407A1 (en) 2019-07-31
KR102728012B1 (ko) 2024-11-11
WO2018057968A1 (en) 2018-03-29
US20190224322A1 (en) 2019-07-25
KR20190066608A (ko) 2019-06-13
AU2017331340B2 (en) 2023-09-28
US20250009886A1 (en) 2025-01-09
MX2019003052A (es) 2019-11-25
JP2022188046A (ja) 2022-12-20
JP2025106324A (ja) 2025-07-15
CA3037531A1 (en) 2018-03-29
CN109890365A (zh) 2019-06-14
JP2019529564A (ja) 2019-10-17
JP7716175B2 (ja) 2025-07-31
AU2017331340A1 (en) 2019-04-11
JP7731333B2 (ja) 2025-08-29

Similar Documents

Publication Publication Date Title
MX2023003010A (es) Composiciones para compuestos de agente terapeutico de molecula peque?a.
ECSP16084431A (es) Composiciones estables de yodo no en complejo y métodos de uso
DOP2019000117A (es) Nuevos derivados de quinolina
DOP2020000023A (es) Nuevos derivados de quinolina
PE20150132A1 (es) Compuestos d-aminoacidos para enfermedad hepatica
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
BR112014025564B8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma
AR072224A1 (es) Derivados de pirimidona sustituidos
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
BR112012018635A2 (pt) composição para exterminar parasita de animal e método para exterminar parasita de animal
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
CL2020002891A1 (es) Nuevos derivados de quinolina
ZA201607097B (en) Liquid formulation comprising gm-csf neutralizing compound
CL2019002677A1 (es) Composición adhesiva y método de preparación de la misma.
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112013010918B8 (pt) composição compreendendo sal de cloridrato de alumínio, método de fabricação do referido sal e usos do mesmo
AR063925A1 (es) Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas
MX2020005087A (es) Composiciones de acido ascorbico estables y metodos de uso de las mismas.
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
UY35535A (es) ?Derivados de fenil sulfonamidas?.
AR111550A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico
AR077371A1 (es) DERIVADOS DE PIRAZOL, SU PREPARACIoN Y SU APLICACIoN EN LA TERAPIA DEL CÁNCER
ES2422730T3 (es) Sales de tiotropio, procedimiento para su preparación, así como formulaciones de medicamentos que las contienen
PA8543401A1 (es) Composicion farmaceutica a base de macrolidos para la aplicacion local en oftalmologia
PE20110564A1 (es) Composicion que tiene quitosano hidroxipropilo, amida y/o alquilo de acido dicarboxilico